Adil joined Glycostem in 2020 as Senior Research Manager and led the development of novel engineered NK cell platforms and clinical research as team lead, as well as contributed to multiple projects such as mechanism of action and combination therapies. Since October 2023, Adil serves as the Director of Business Development at Glycostem.
Previously, Adil performed his PhD and post-doctoral studies at Karolinska Institute, Sweden, on MHC-class-I restricted-peptide based immunomodulation of T cells and NK cells, and on developing novel genetic modification strategies for NK cells, respectively. From 2015 until 2020, Adil worked as an Assistant Professor/PI at the Nova Southeastern University (NSU) Cell Therapy Institute, FL, USA, focussed his research on investigating NK cell interactions with tumors and developing innovative novel NCR-, TCR- and CAR-based genetically modified NK cell immunotherapies. Furthermore, Adil established and directed the Cell Therapy Core Facility at NSU, for the design, development and pre-clinical evaluation of novel cell therapy products. Additionally, Adil is a co-founder and shareholder of Vycellix Inc. and has 20+ peer reviewed publications as well as multiple patent applications.